Clinical Trial Research
Bio-Path Holdings Announces Dosing of First Patient in a Phase I Clinical Trial of Its Liposomal Grb-2 Cancer Drug Candidate
Published in Cancer Gene Therapy Week, August 9th, 2010
Bio-Path Holdings, Inc., (OTCBB: BPTH) ("Bio-Path"), a biotechnology company with drug development operations in Houston, Texas, announced that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS). Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms microscopic-sized vehicles to safely deliver these drugs to their intended target cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week
More Articles from Cancer Gene Therapy Week
- Cancer Gene Therapy
New cancer gene therapy study findings have been reported from Medical Research Council Laboratory of Molecular Biology - Interleukins
Findings in interleukins reported from Louisiana State University - Drug Development
Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease - Breast Cancer
National University, Department of Pathology describes research in breast cancer - Adeno-Associated Virus
New adeno-associated virus research from Weill Cornell Medical College, Department of Genetic Medicine discussed - Chronic Myeloid Leukemia
New chronic myeloid leukemia data have been reported by V. Vonka and co-authors - More from this issue of Cancer Gene Therapy Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
